^(125)I放射性粒子植入联合支气管动脉灌注化疗治疗晚期非小细胞肺癌效果及安全性的meta分析  

Meta-analysis on efficacy and safety of ^(125)I seed implantation combined with bronchial arterial infusion chemotherapy for advanced non-small cell lung cancer

作　　者：冯江峰[1] 赵振华[1] 王挺[1] 杨建峰[1] 胡红杰[2] FENG Jiangfeng;ZHAO Zhenhua;WANG Ting;YANG Jianfeng;HU Hongjie(Department of Radiology,Shaoxing Hospital of Zhejiang University(Shaoxing People’s Hospital),Zhejiang,Shaoxing 312000,China;Department of Radiology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Zhejiang,Hangzhou 310016,China)

机构地区：[1]浙江大学绍兴医院(绍兴市人民医院)放射科,浙江绍兴312000 [2]浙江大学医学院附属邵逸夫医院放射科,浙江杭州310016

出　　处：《中国医药科学》2022年第8期37-41,共5页China Medicine And Pharmacy

基　　金：浙江省医药卫生科技计划(2019KY228)。

摘　　要：目的系统评价^(125)I放射性粒子植入联合支气管动脉灌注化疗与单纯支气管动脉灌注或静脉化疗治疗晚期非小细胞肺癌的效果及安全性。方法通过计算机检索PubMed、Cochrane Library、中国知识资源总库(CNKI)、万方、维普、中国生物医学文献数据库(CBM)等国内外数据库中2000年1月1日至2020年12月31日有关^(125)I放射性粒子植入联合支气管动脉灌注化疗方案治疗晚期非小细胞肺癌的随机对照试验(RCT)研究文献,提取客观缓解率、疾病控制率、中位生存时间、1年生存率及不良反应发生率等指标,采用RevMan 5.3及STATA 15.1统计学软件进行meta分析。结果最终纳入10篇文献,共计893例晚期非小细胞肺癌患者。meta分析结果显示,^(125)I放射性粒子植入联合支气管动脉灌注化疗治疗晚期非小细胞肺癌明显优于单纯支气管动脉灌注或静脉化疗,客观缓解率(OR=1.91,95%CI:1.61~2.21,P<0.05),疾病控制率(OR=1.30,95%CI:1.20~1.42,P<0.05),中位生存时间(97.3 d,95%CI:60.00~134.59,P<0.05),1年生存率(OR=1.43,95%CI:1.22~1.67,P<0.05),差异有统计学意义(P<0.05)。两组恶心呕吐发生率(OR=0.70,95%CI:0.42~1.15,P=0.16)、骨髓抑制发生率(OR=1.04,95%CI:0.65~1.66,P=0.88)比较,差异无统计学意义(P>0.05)。结论^(125)I放射性粒子植入联合支气管动脉灌注化疗对晚期NSCLC的有效率明显高于单纯支气管动脉灌注或静脉化疗,且具有良好的安全性,可作为晚期非小细胞肺癌局部治疗的有效治疗手段。Objective To evaluate the efficacy and safety of ^(125)I seed implantation combined with bronchial arterial infusion chemotherapy versus bronchial arterial infusion or intravenous chemotherapy in the treatment of advanced non-small cell lung cancer.Methods PubMed and Cochrane were searched by computer Library,CNKI,Wanfang,VIP,CBM and other domestic and foreign databases from January 1,2000 to December 31,2020 about ^(125)I seed implantation combined with bronchial arterial infusion chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC),objective response rate,disease control rate,median survival time,1-year survival rate and incidence of adverse reactions were extracted,and meta-analysis was performed using RevMan 5.3 and STATA 15.1 statistical software.Results A total of 893 patients with advanced NSCLC were included in 10 literatures.Meta-analysis results showed that ^(125)I seed implantation combined with bronchial arterial infusion chemotherapy was significantly superior to bronchial arterial infusion or intravenous chemotherapy alone in the treatment of advanced NSCLC,with objective remission rate(OR=1.91,95%CI:1.61-2.21,P<0.05),disease control rate(OR=1.30,95%CI:1.20-1.42,P<0.05),median survival time(97.3 days,95%CI:60.00-134.59,P<0.05),and 1-year survival rate(OR=1.43,95%CI:1.22-1.67,P<0.05),the differences were statistically significant(P<0.05).There were no significant differences in the incidence of nausea and vomiting(OR=0.70,95%CI:0.42-1.15,P=0.16)and bone marrow suppression(OR=1.04,95%CI:0.65-1.66,P=0.88)between the two groups(P>0.05).Conclusion ^(125)I seed implantation combined with bronchial arterial infusion chemotherapy is an effective treatment for local treatment of advanced NSCLC.

关 键 词：非小细胞肺癌 粒子植入 支气管动脉灌注化疗 META分析 

分 类 号：R734.2[医药卫生—肿瘤]